Useful links and resources

Resources and valuable links around nausea and vomiting of pregnancy (NVP), commonly called Morning Sickness, are listed below:*

Healthcare Professional Resources:

ACOG (American Congress of Obstetricians and Gynecologists)The nation's leading group of physicians providing healthcare for women.*

APGO (Association of Professors of Gynecology and Obstetrics)
Non-profit, membership-based organization for women's health educators.*

WELLMOM OBSTETRICS APP from APGO (Association of Professors of Gynecology and Obstetrics)APGO WellMom "Managing Nausea and Vomiting of Pregnancy (NVP)" is the only app designed to raise awareness of NVP, educating all parties affected by the condition and managing and treating symptoms.

AWHONN (Association of Women's Health, Obstetric and Neonatal Nurses)
Non-profit membership -based organization that promotes the health of women and newborns.*

ACNM (American College of Nurse-Midwives)
Professional association that represents certified nurse-midwives and certified midwives in the United States.*

Bendectin.com
Provides history of Bendectin.*

MotherToBaby.org (formally known as Organization of Teratology Information Specialists)
Non-profit organization dedicated to providing accurate, evidence-based, clinical information to patients and healthcare professionals about exposure during pregnancy and lactation.*

NPWH (National Association of Nurse Practitioners in Women's Health)
Represents nurse practitioners who provide care to women in the primary care setting as well as in women's health specialty practices.*

Expectant Mother Resources:

American Pregnancy Association
Non-profit health organization committed to promoting reproductive and pregnancy wellness through education, research, advocacy and community awareness.*

Everyday Health
Organization that provides advice from medical experts, tips from parents, and health and wellness news. Sections are dedicated to each stage of pregnancy so that women can find the information that is most relevant to them.*

March of Dimes
Non-profit organization focused on preventing birth defects, premature birth and infant mortality. Site provides information and resources for individuals and healthcare professionals to help women have healthy pregnancies and healthy babies.*

Mayo Clinic
Non-profit worldwide leader in medical care, research and education.*

MedlinePlus
National Institutes of Health website offering reliable, up-to-date health information on a variety of topics.*

Parents Magazine: Blogs
Blog that is part of www.parents.com and that delivers the top mom and dad blogs on baby development, parenting advice, tips on raising kids and much more.*

U.S. Department of Health and Human Services Office on Women's Health: Pregnancy
Provides information about what women can do before, during, and after pregnancy to help their babies get a healthy start on life.*

What to Expect
Organization that provides a variety of information for pregnant mothers. Topics include pregnancy symptoms, labor and delivery, pregnancy fitness and much more.*

What to Expect: Word of Mom Blog
A blog written from mothers’ points-of-view. Provides valuable advice, the latest news and inspiration for expectant women.*

*Links to other websites

Links on Duchesnay USA websites to third-party websites are provided merely as a convenience and do not constitute an endorsement of those websites or the products, services, or content found on them. Duchesnay USA has no control over the websites to which it may link, makes no representation or warranty of any kind as to the currency, quality, completeness, or accuracy of that content and shall have no liability or responsibility for any damages or injuries of any kind arising from such content or information. These external websites are governed by their own terms of use and privacy policies to which you are directed.

Indication and Important Safety Information

INDICATION

Diclegis® is a fixed-dose combination drug product of doxylamine succinate, an antihistamine, and pyridoxine hydrochloride, a vitamin B6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

LIMITATIONS OF USE

Diclegis® has not been studied in women with hyperemesis gravidarum.

IMPORTANT SAFETY INFORMATION

Diclegis® is contraindicated in women with known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride, or any inactive ingredient in the formulation. Diclegis® is also contraindicated in combination with monoamine oxidase inhibitors (MAOIs) as MAOIs intensify and prolong the adverse CNS effects of Diclegis®. Use of MAOIs may also prolong and intensify the anticholinergic (drying) effects of antihistamines.

Diclegis® may cause somnolence due to the anticholinergic properties of doxylamine succinate, an antihistamine. Women should avoid engaging in activities requiring complete mental alertness, such as driving or operating heavy machinery, while using Diclegis® until cleared to do so by their healthcare provider.

Use of Diclegis® is not recommended if a woman is concurrently using CNS depressants, such as alcohol or sedating medications, including other antihistamines (present in some cough and cold medications), opiates, and sleep aids. The combination of Diclegis® and CNS depressants could result in severe drowsiness leading to falls or other accidents.

Diclegis® has anticholinergic properties and should be used with caution in women who have: (1) asthma, (2) increased intraocular pressure, (3) an eye problem called narrow angle glaucoma, (4) a stomach problem called stenosing peptic ulcer, (5) pyloroduodenal obstruction, or (6) a urinary bladder problem called bladder-neck obstruction.

Fatalities have been reported from doxylamine overdose in children. Children appear to be at a high risk for cardiorespiratory arrest. However, the safety and effectiveness of Diclegis® in children under 18 years of age have not been established.

Diclegis® is a delayed-release formulation; therefore, signs and symptoms of intoxication may not be apparent immediately. Signs and symptoms of overdose may include restlessness, dryness of mouth, dilated pupils, sleepiness, vertigo, mental confusion, and tachycardia. If you suspect an overdose or seek additional overdose information, you can contact a poison control center at 1-800-222-1222.

Diclegis® is intended for use in pregnant women.

Women should not breast-feed while using Diclegis® because the antihistamine component (doxylamine succinate) in Diclegis® can pass into breast milk. Excitement, irritability, and sedation have been reported in nursing infants presumably exposed to doxylamine succinate through breast milk. Infants with apnea or other respiratory syndromes may be particularly vulnerable to the sedative effects of Diclegis® resulting in worsening of their apnea or respiratory conditions.

To report suspected adverse reactions, contact Duchesnay Inc. at 1-855-722-7734 or medicalinfo@duchesnayusa.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Tablet(s) shown throughout the site are not actual size.

 

Please click here for full Prescribing Information.

 

Site references

  1. Diclegis® Prescribing Information, Bryn Mawr, PA: Duchesnay USA Inc., 2013.
  2. Whitehead, S. A., et al. (1992). “Characterisation of nausea and vomiting in early pregnancy: a survey of 1000 women.” J Obstet Gynecol 12(6): 364-369.
  3. Gadsby, R., et al. (1993). “A prospective study of nausea and vomiting during pregnancy.” Br J Gen Pract 43(371): 245-248.
  4. Vellacott, I. D., et al. (1988). “Nausea and vomiting in early pregnancy.” Int J Gynecol Obstet 27(1): 57-62.
  5. Nausea and Vomiting of Pregnancy, ACOG Practice Bulletin #153: Clinical Management Guidelines for Obstetrician-Gynecologists 2015; 126, 3:e12-e24.
  6. Association of Professors of Gynecology and Obstetrics Continuing Series on Women’s Health: Nausea and Vomiting of Pregnancy, February 2015.
  7. McKeigue, P. M., et al. (1994). “Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies.” Teratology 50: 27-37.